Research Team Finds New Dual Benefit Mode of Action for a Drug Candidate to Fight COVID-19
Lead author Dr. André Schreiber (left) and professor Stephan Ludwig have found a new type of dual action for an anti-Covid 19 drug candidate. This might provide the basis for…